ecteinascidin 743 has been researched along with buthionine sulfoximine in 1 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (buthionine sulfoximine) | Trials (buthionine sulfoximine) | Recent Studies (post-2010) (buthionine sulfoximine) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 2,460 | 8 | 408 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brouwer, KL; Lee, JK; Leslie, EM; Zamek-Gliszczynski, MJ | 1 |
1 other study(ies) available for ecteinascidin 743 and buthionine sulfoximine
| Article | Year |
|---|---|
Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity.
Topics: Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Bile; Blotting, Western; Buthionine Sulfoximine; Cell Separation; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Dexamethasone; Dioxoles; Enzyme Inhibitors; Hepatocytes; In Vitro Techniques; L-Lactate Dehydrogenase; Liver; Male; Rats; Rats, Wistar; Tetrahydroisoquinolines; Trabectedin | 2008 |